BETA


2013/0005(NLE) EU/Russia agreement: drug precursors

Progress: Procedure completed

RoleCommitteeRapporteurShadows
Lead INTA PROUST Franck (icon: PPE PPE) KELLER Ska (icon: Verts/ALE Verts/ALE)
Committee Opinion ENVI
Committee Opinion LIBE
Committee Opinion JURI ZIOBRO Zbigniew (icon: EFD EFD)
Lead committee dossier:
Legal Basis:
TFEU 207-p4, TFEU 218-p6a

Events

2014/06/04
   Final act published in Official Journal
Details

PURPOSE: the conclusion of an agreement between the European Union and the Russian Federation on drug precursors.

NON-LEGISLATIVE ACT: Council Decision 2014/318/EU on the conclusion, on behalf of the European Union, of the Agreement between the European Union and the Russian Federation on drug precursors.

BACKGROUND: the European Union and the Russian Federation should strengthen their cooperation to prevent diversion of drug precursors from the legal trade, in order to counter the illicit manufacture of narcotic drugs and psychotropic substances.

In accordance with Council Decision 2013/263/EU, the Agreement between the European Union and the Russian Federation on drug precursors was signed on 4 June 2013, subject to its conclusion at a later date.

The Agreement should ensure full respect of fundamental rights, in particular a high level of protection for the processing and transfer of personal data between the Parties to the Agreement.

It is now appropriate to conclude this agreement on behalf of the European Union.

CONTENT: by means of this decision, the Council approves on behalf of the European Union, with the consent of the European Parliament, an agreement between the European Union and the Russian Federation on drug precursors.

Objective of the agreement: the agreement aims to strengthen the cooperation between the European Union and Russia to prevent diversion of drug precursors from the legal trade to counter illicit manufacture of narcotic drugs and psychotropic substances .

Scope: from a technical point of view, it is stipulated that the Parties shall assist each other in the form and under the conditions provided for in the Agreement, in particular by:

· monitoring the trade between the Parties in the precursors with the aim of preventing their use for illicit purposes,

· providing mutual assistance for the purpose of prevention of diversion of such precursors.

The measures shall apply to the precursors listed in Annex I of the Agreement (referred to as "scheduled precursors").

Implementing measures: it is envisaged that the Parties shall inform each other in writing about their respective competent authorities. These authorities shall communicate directly with one another for the purposes of this Agreement. The competent authorities of the Parties shall inform each other on their own initiative whenever they have reasonable grounds to believe that scheduled precursors in legitimate trade between the Parties may be diverted to the illicit manufacture of narcotic drugs or psychotropic substances.

Exceptions to the obligation to provide mutual assistance: provisions are made in the Agreement for derogations from the principle of mutual assistance in cases where a Party is of the opinion that assistance under this Agreement would be likely to prejudice the sovereignty the security, the public policy or other essential interests.

Exchange of personal data: as this Agreement may occasionally imply an exchange of personal data, it includes specific provisions on data protection in order to provide sufficient protection for citizens in the use of their data. An annex clarifies certain definitions or principles relating to data protection.

Scientific and technical cooperation: provisions are made to facilitate cooperation between the Parties with a view to the identification of new diversion methods, as well as appropriate counter-measures.

Institutional framework: a Joint Follow-Up Expert Group is established which consists of the representatives of competent authorities of the Parties. It shall be responsible for the management of the Agreement and its proper implementation.

Duration of the agreement: the agreement is concluded for a period of 5 years at the end of which it will be automatically/tacitly renewed for successive new periods of 5 years, until one of the Parties notifies the other in writing of its intention to terminate the agreement. It may be amended by common agreement.

ENTRY INTO FORCE: the decision enters into force on 17.02.2014. The agreement enters into force on 1 April 2014.

2014/02/17
   EP/CSL - Act adopted by Council after consultation of Parliament
2014/02/17
   EP - End of procedure in Parliament
2014/02/17
   CSL - Council Meeting
2013/11/20
   EP - Results of vote in Parliament
2013/11/20
   EP - Decision by Parliament
Details

The European Parliament adopted a legislative resolution on the on the draft Council Decision on the conclusion, on behalf of the European Union, of the Agreement between the European Union and the Russian Federation on drug precursors.

Parliament gave its consent to the conclusion of the Agreement.

Documents
2013/10/22
   EP - Committee report tabled for plenary, 1st reading/single reading
Details

The Committee on International Trade adopted the report by Franck PROUST (EPP, FR) on the draft Council Decision on the conclusion, on behalf of the European Union, of the Agreement between the European Union and the Russian Federation on drug precursors.

It recommended that the European Parliament give its consent to the conclusion. It also indicated that it would be necessary to monitor its implementation and that it hoped for the conclusion to be followed up by other similar agreements with other third countries in the years to come.

Documents
2013/10/14
   EP - Vote in committee
2013/10/08
   EP - Committee referral announced in Parliament
2013/09/25
   EP - Committee draft report
Documents
2013/09/05
   CSL - Legislative proposal
Details

PURPOSE: the conclusion of an agreement between the European Union and Russia on drug precursors.

PROPOSED ACT: Council Decision.

PARLIAMENT’S ROLE: Parliament’s consent is required for the Council to conclude the agreement.

BACKGROUND: the European Union and the Russian Federation should strengthen their cooperation to prevent diversion of drug precursors from the legal trade, in order to counter the illicit manufacture of narcotic drugs and psychotropic substances.

In accordance with a Council Decision, the Agreement between the European Union and the Russian Federation on drug precursors was signed on 4 June 2013, subject to its conclusion at a later date.

The Agreement should ensure full respect of fundamental rights, in particular a high level of protection for the processing and transfer of personal data between the Parties to the Agreement.

It is now appropriate to conclude this Agreement on behalf of the European Union.

IMPACT ASSESSMENT: no impact assessment was undertaken. The Member States were, however, kept regularly informed on the negotiations at the most appropriate level of the Council on the Draft Agreement.

LEGAL BASIS: Article 207 (4) first indent in conjunction with Article 218 (6) (a) of the Treaty on the Functioning of the European Union (TFEU).

CONTENT: by this proposal, the Council is invited to adopt a decision on the conclusion of an agreement between the European Union and Russia on drug precursors.

The text of the Agreement is attached to the proposed Decision. Its main characteristics may be summarised as follows:

Purpose of the Agreement: the draft Agreement aims to strengthen the cooperation between the European Union and Russia to prevent diversion of drug precursors from the legal trade to counter illicit manufacture of narcotic drugs and psychotropic substances .

Scope: from a technical point of view, it is stipulated that the Parties shall assist each other in the form and under the conditions provided for in the Agreement, in particular by:

monitoring the trade between the Parties in the precursors with the aim of preventing their use for illicit purposes, providing mutual assistance for the purpose of prevention of diversion of such precursors.

The measures shall apply to the precursors listed in Annex I of the Agreement (referred to as "scheduled precursors").

Implementation measures: the Parties shall inform each other in writing about their respective competent authorities. These authorities shall communicate directly with one another for the purposes of this Agreement. The competent authorities of the Parties shall inform each other on their own initiative whenever they have reasonable grounds to believe that scheduled precursors in legitimate trade between the Parties may be diverted to the illicit manufacture of narcotic drugs or psychotropic substances.

The Parties shall within the scope of this agreement provide each other mutual assistance through exchange of information referred to in the draft Agreement to prevent the diversion of scheduled precursors to the illicit manufacture of narcotic drugs or psychotropic substances. They shall, in accordance with the legislation of the Parties, take appropriate steps to prevent diversion .

Exceptions to the obligation to provide mutual assistance: provisions are made in the Agreement for derogations from the principle of mutual assistance in cases where a Party is of the opinion that assistance under this Agreement would be likely to prejudice the sovereignty the security, the public policy or other essential interests.

Exchange of personal data: as this Agreement may occasionally imply an exchange of personal data, it includes specific provisions on data protection in order to provide sufficient protection for citizens in the use of their data. An annex clarifies certain definitions or principles relating to data protection.

Scientific and technical cooperation: p rovisions are made to facilitate cooperation between the Parties with a view to the identification of new diversion methods, as well as appropriate counter-measures.

Institutional framework: a Joint Follow-Up Expert Group is established which consists of the representatives of competent authorities of the Parties. It shall be responsible for the management of the Agreement and its proper implementation.

Duration of the Agreement: this Agreement shall be concluded for five years at the end of which it is automatically/tacitly renewed for further successive five year periods until one of the Parties notifies the other Party in writing of its intention to terminate this present agreement.

BUDGETARY IMPLICATION: the proposal has no budgetary implications for the Union budget. Nevertheless, it is stipulated in the Agreement that each Party shall bear the costs it incurs arising from the measures to implement the Agreement.

Documents
2013/09/04
   EC - Legislative proposal published
Details

PURPOSE: the conclusion of an agreement between the European Union and Russia on drug precursors.

PROPOSED ACT: Council Decision.

PARLIAMENT’S ROLE: Parliament’s consent is required for the Council to conclude the agreement.

BACKGROUND: the European Union and the Russian Federation should strengthen their cooperation to prevent diversion of drug precursors from the legal trade, in order to counter the illicit manufacture of narcotic drugs and psychotropic substances.

In accordance with a Council Decision, the Agreement between the European Union and the Russian Federation on drug precursors was signed on 4 June 2013, subject to its conclusion at a later date.

The Agreement should ensure full respect of fundamental rights, in particular a high level of protection for the processing and transfer of personal data between the Parties to the Agreement.

It is now appropriate to conclude this Agreement on behalf of the European Union.

IMPACT ASSESSMENT: no impact assessment was undertaken. The Member States were, however, kept regularly informed on the negotiations at the most appropriate level of the Council on the Draft Agreement.

LEGAL BASIS: Article 207 (4) first indent in conjunction with Article 218 (6) (a) of the Treaty on the Functioning of the European Union (TFEU).

CONTENT: by this proposal, the Council is invited to adopt a decision on the conclusion of an agreement between the European Union and Russia on drug precursors.

The text of the Agreement is attached to the proposed Decision. Its main characteristics may be summarised as follows:

Purpose of the Agreement: the draft Agreement aims to strengthen the cooperation between the European Union and Russia to prevent diversion of drug precursors from the legal trade to counter illicit manufacture of narcotic drugs and psychotropic substances .

Scope: from a technical point of view, it is stipulated that the Parties shall assist each other in the form and under the conditions provided for in the Agreement, in particular by:

monitoring the trade between the Parties in the precursors with the aim of preventing their use for illicit purposes, providing mutual assistance for the purpose of prevention of diversion of such precursors.

The measures shall apply to the precursors listed in Annex I of the Agreement (referred to as "scheduled precursors").

Implementation measures: the Parties shall inform each other in writing about their respective competent authorities. These authorities shall communicate directly with one another for the purposes of this Agreement. The competent authorities of the Parties shall inform each other on their own initiative whenever they have reasonable grounds to believe that scheduled precursors in legitimate trade between the Parties may be diverted to the illicit manufacture of narcotic drugs or psychotropic substances.

The Parties shall within the scope of this agreement provide each other mutual assistance through exchange of information referred to in the draft Agreement to prevent the diversion of scheduled precursors to the illicit manufacture of narcotic drugs or psychotropic substances. They shall, in accordance with the legislation of the Parties, take appropriate steps to prevent diversion .

Exceptions to the obligation to provide mutual assistance: provisions are made in the Agreement for derogations from the principle of mutual assistance in cases where a Party is of the opinion that assistance under this Agreement would be likely to prejudice the sovereignty the security, the public policy or other essential interests.

Exchange of personal data: as this Agreement may occasionally imply an exchange of personal data, it includes specific provisions on data protection in order to provide sufficient protection for citizens in the use of their data. An annex clarifies certain definitions or principles relating to data protection.

Scientific and technical cooperation: p rovisions are made to facilitate cooperation between the Parties with a view to the identification of new diversion methods, as well as appropriate counter-measures.

Institutional framework: a Joint Follow-Up Expert Group is established which consists of the representatives of competent authorities of the Parties. It shall be responsible for the management of the Agreement and its proper implementation.

Duration of the Agreement: this Agreement shall be concluded for five years at the end of which it is automatically/tacitly renewed for further successive five year periods until one of the Parties notifies the other Party in writing of its intention to terminate this present agreement.

BUDGETARY IMPLICATION: the proposal has no budgetary implications for the Union budget. Nevertheless, it is stipulated in the Agreement that each Party shall bear the costs it incurs arising from the measures to implement the Agreement.

Documents
2013/05/27
   CSL - Document attached to the procedure
Documents
2013/05/27
   PT_PARLIAMENT - Contribution
Documents
2013/04/30
   EP - Committee opinion
Documents
2013/04/23
   EDPS - Document attached to the procedure
Details

Opinion of the European Data Protection Supervisor on the proposal for a Council decision on the conclusion of the Agreement between the European Union and the

Russian Federation on drug precursors .

On 21 January 2013, the Commission adopted a proposal for a Council decision on the conclusion of the Agreement between the European Union and the Russian Federation on drug precursors. The proposal was sent to the EDPS for consultation on the same day. The EDPS had been previously consulted by the Commission. The present Opinion builds on the advice provided at that occasion and on the EDPS Opinion on the amendments to the Regulations on EU internal and external trade in drug precursors (the objective of which is to prevent the diversion from legitimate trade of the substances used to illicitly manufacture narcotic drugs and psychotropic substances).

Data protection: the EDPS welcomes the provisions on the protection of personal data in the text of the agreement and the inclusion in the Annex of data protection principles to be respected by the Parties. The EDPS suggests including an explicit reference to the applicability of EU national laws implementing Directive 95/46/EC to the transfers of personal data by the EU to Russian authorities and to the processing of personal data by EU authorities.

The EDPS also recommends specifying all the categories of personal data that might be exchanged. Furthermore, additional safeguards, such as shorter retention periods and stricter security measures should be included in the agreement or in Annex II for data relating to suspect transactions.

Additional provisions: the EDPS also recommends the inclusion of the following provisions:

· adding the provisions on ‘data security’ and the specific requirements for processing ‘sensitive data’;

· specifying the procedures for making effective the principles of ‘transparency’ and ‘rights of access, rectification, erasure and blocking of data’ in the text of the agreement or in the Annex;

· as regards ‘ onward transfers’ , it should be added that the competent authorities of the Parties should not transfer personal data to other national recipients unless the recipient provides adequate protection and for the purposes for which the data have been transmitted;

· as regards the principle of ‘redress’, it should be specified that the term ‘competent authorities’, used in the rest of the agreement in a different context, refers here to authorities competent for the protection of personal data and the supervision of their processing;

· the relevant authorities and the practical information on existing remedies should be mentioned in the agreement or at least in letters exchanged between the parties or in documents accompanying the agreement;

· as regards the principle on ‘exceptions to the rights of transparency and direct access’: it should be specified that, in cases where the right of access cannot be granted to data subjects, indirect access through EU national data protection authorities should be provided.

It should also be specified that the data protection supervisory authorities of the Parties should jointly review the implementation of the agreement, either in the framework of the joint follow-up expert group, or as a separate process. In addition, if the independence of the relevant Russian supervisory authority is not sufficiently established, it should be specified that EU national data protection authorities should be involved in the supervision of the implementation of the agreement by Russian authorities. The results of the review should be reported to the European Parliament and to the Council, where needed with full respect of confidentiality. The EDPS also recommends completing Article 12 of the agreement with a clause allowing any Party to suspend or terminate the agreement in the event of a breach of the other Party's obligations under the agreement, including as regards compliance with the data protection principles.

2013/02/20
   EP - PROUST Franck (PPE) appointed as rapporteur in INTA
2013/02/20
   EP - ZIOBRO Zbigniew (EFD) appointed as rapporteur in JURI
2013/01/21
   EP - Preparatory document
Details

PURPOSE: the conclusion of an agreement between the European Union and the Russian Federation on drug precursors.

PROPOSED ACT: Council Decision.

PARLIAMENT'S ROLE: Parliament's consent is required for the Council to conclude the agreement.

BACKGROUND: on 23 March 2009, the Council authorised the Commission to open negotiations with the Russian Federation for an Agreement on drug precursors. Following the launch of negotiations in September 2009, four negotiating rounds took place.

In September 2012, the text of the Agreement was finally agreed between the Parties.

It is now appropriate to conclude this Agreement on behalf of the European Union.

IMPACT ASSESSMENT: no impact assessment was undertaken. The Member States were, however, kept regularly informed on the negotiations at the most appropriate level of the Council on the Draft Agreement.

LEGAL BASIS: Article 207 (4) first indent in conjunction with Article 218 (6) (a) of the Treaty on the Functioning of the European Union (TFEU).

CONTENT: this Decision seeks to conclude an agreement between the European Union and Russia on drug precursors.

Purpose of the Agreement: the Draft Agreement aims to strengthen the cooperation between the European Union and Russia to prevent diversion of drug precursors from the legal trade to counter illicit manufacture of narcotic drugs and psychotropic substances .

Scope: from a technical point of view, it is stipulated that the Parties shall assist each other in the form and under the conditions provided for in the Agreement, in particular by:

monitoring the trade between the Parties in the precursors with the aim of preventing their use for illicit purposes, providing mutual assistance for the purpose of prevention of diversion of such precursors.

The measures shall apply to the precursors listed in Annex I of the Agreement (referred to as "scheduled precursors").

Exceptions to the obligation to provide mutual assistance: provisions are made in the Agreement for derogations from the principle of mutual assistance in cases where a Party is of the opinion that assistance under this Agreement would be likely to prejudice the sovereignty the security, the public policy or other essential interests.

Exchange of personal data: as this Agreement may occasionally imply an exchange of personal data, it includes specific provisions on data protection in order to provide sufficient protection for citizens in the use of their data. An annex clarifies certain definitions or principles relating to data protection.

Scientific and technical cooperation:

Provisions are made to facilitate cooperation between the Parties with a view to the identification of new diversion methods, as well as appropriate counter-measures.

Institutional framework: a Joint Follow-Up Expert Group is established which consists of the representatives of competent authorities of the Parties. It shall be responsible for the management of the Agreement and its proper implementation.

It should be noted that unless otherwise provided by this Agreement, its provisions shall not affect the obligations of the Parties under any other international agreement.

BUDGETARY IMPLICATION: the proposal has no budgetary implications for the Union budget. Nevertheless, it is stipulated in the Agreement that each Party shall shall bear the costs it incurs arising from the measures to implement the Agreement.

Documents

History

(these mark the time of scraping, not the official date of the change)

docs/3
date
2013-09-05T00:00:00
docs
url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=12221%2F13&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC title: 12221/2013
summary
type
Legislative proposal
body
CSL
docs/4
date
2013-05-28T00:00:00
docs
url: http://www.connefof.europarl.europa.eu/connefof/app/exp/COM(2013)0004 title: COM(2013)0004
type
Contribution
body
PT_PARLIAMENT
docs/5
date
2013-05-27T00:00:00
docs
url: https://connectfolx.europarl.europa.eu/connefof/app/exp/COM(2013)0004 title: COM(2013)0004
type
Contribution
body
PT_PARLIAMENT
events/1/date
Old
2013-09-05T00:00:00
New
2013-09-04T00:00:00
links/National parliaments/url
Old
http://www.ipex.eu/IPEXL-WEB/dossier/dossier.do?code=NLE&year=2013&number=0005&appLng=EN
New
https://ipexl.europarl.europa.eu/IPEXL-WEB/dossier/code=NLE&year=2013&number=0005&appLng=EN
docs/1/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE508.205&secondRef=02
New
https://www.europarl.europa.eu/doceo/document/JURI-AD-508205_EN.html
docs/3/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE514.575
New
https://www.europarl.europa.eu/doceo/document/INTA-PR-514575_EN.html
events/0/docs/0/url
Old
http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/com/2013/0004/COM_COM(2013)0004_EN.pdf
New
http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2013/0004/COM_COM(2013)0004_EN.pdf
events/2/type
Old
Committee referral announced in Parliament, 1st reading/single reading
New
Committee referral announced in Parliament
events/3/type
Old
Vote in committee, 1st reading/single reading
New
Vote in committee
events/4/docs/0/url
Old
http://www.europarl.europa.eu/doceo/document/A-7-2013-0342_EN.html
New
https://www.europarl.europa.eu/doceo/document/A-7-2013-0342_EN.html
events/6
date
2013-11-20T00:00:00
type
Decision by Parliament
body
EP
docs
url: https://www.europarl.europa.eu/doceo/document/TA-7-2013-0479_EN.html title: T7-0479/2013
summary
events/6
date
2013-11-20T00:00:00
type
Decision by Parliament, 1st reading/single reading
body
EP
docs
url: http://www.europarl.europa.eu/doceo/document/TA-7-2013-0479_EN.html title: T7-0479/2013
summary
procedure/Modified legal basis
Rules of Procedure EP 159
procedure/Other legal basis
Rules of Procedure EP 159
committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
International Trade
committee
INTA
rapporteur
name: PROUST Franck date: 2013-02-20T00:00:00 group: European People's Party (Christian Democrats) abbr: PPE
shadows
name: KELLER Ska group: Greens/European Free Alliance abbr: Verts/ALE
committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
International Trade
committee
INTA
date
2013-02-20T00:00:00
rapporteur
name: PROUST Franck group: European People's Party (Christian Democrats) abbr: PPE
shadows
name: KELLER Ska group: Greens/European Free Alliance abbr: Verts/ALE
committees/2
type
Committee Opinion
body
EP
associated
False
committee_full
Legal Affairs
committee
JURI
rapporteur
name: ZIOBRO Zbigniew date: 2013-02-20T00:00:00 group: Europe of Freedom and Democracy abbr: EFD
committees/2
type
Committee Opinion
body
EP
associated
False
committee_full
Legal Affairs
committee
JURI
date
2013-02-20T00:00:00
rapporteur
name: ZIOBRO Zbigniew group: Europe of Freedom and Democracy abbr: EFD
events/0
date
2013-01-21T00:00:00
type
Preparatory document
body
EP
docs
summary
events/0
date
2013-01-21T00:00:00
type
Initial legislative proposal published
body
EC
docs
summary
events/4/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A7-2013-342&language=EN
New
http://www.europarl.europa.eu/doceo/document/A-7-2013-0342_EN.html
events/6/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P7-TA-2013-0479
New
http://www.europarl.europa.eu/doceo/document/TA-7-2013-0479_EN.html
procedure/Modified legal basis
Old
Rules of Procedure EP 150
New
Rules of Procedure EP 159
activities
  • date: 2013-01-21T00:00:00 docs: url: http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2013/0004/COM_COM(2013)0004_EN.pdf title: COM(2013)0004 type: Initial legislative proposal published celexid: CELEX:52013PC0004:EN body: EC commission: DG: url: http://ec.europa.eu/taxation_customs/index_en.htm title: Taxation and Customs Union Commissioner: ŠEMETA Algirdas type: Initial legislative proposal published
  • date: 2013-09-05T00:00:00 docs: url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=12221%2F13&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC type: Legislative proposal published title: 12221/2013 body: EC commission: DG: url: http://ec.europa.eu/taxation_customs/index_en.htm title: Taxation and Customs Union Commissioner: ŠEMETA Algirdas type: Legislative proposal published
  • date: 2013-10-08T00:00:00 body: EP type: Committee referral announced in Parliament, 1st reading/single reading committees: body: EP responsible: False committee_full: Environment, Public Health and Food Safety committee: ENVI body: EP shadows: group: Verts/ALE name: KELLER Ska responsible: True committee: INTA date: 2013-02-20T00:00:00 committee_full: International Trade rapporteur: group: PPE name: PROUST Franck body: EP responsible: False committee: JURI date: 2013-02-20T00:00:00 committee_full: Legal Affairs rapporteur: group: EFD name: ZIOBRO Zbigniew body: EP responsible: False committee_full: Civil Liberties, Justice and Home Affairs committee: LIBE
  • date: 2013-10-14T00:00:00 body: EP type: Vote in committee, 1st reading/single reading committees: body: EP responsible: False committee_full: Environment, Public Health and Food Safety committee: ENVI body: EP shadows: group: Verts/ALE name: KELLER Ska responsible: True committee: INTA date: 2013-02-20T00:00:00 committee_full: International Trade rapporteur: group: PPE name: PROUST Franck body: EP responsible: False committee: JURI date: 2013-02-20T00:00:00 committee_full: Legal Affairs rapporteur: group: EFD name: ZIOBRO Zbigniew body: EP responsible: False committee_full: Civil Liberties, Justice and Home Affairs committee: LIBE
  • body: EP docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A7-2013-342&language=EN type: Committee report tabled for plenary, 1st reading/single reading title: A7-0342/2013 type: Committee report tabled for plenary, 1st reading/single reading committees: body: EP responsible: False committee_full: Environment, Public Health and Food Safety committee: ENVI body: EP shadows: group: Verts/ALE name: KELLER Ska responsible: True committee: INTA date: 2013-02-20T00:00:00 committee_full: International Trade rapporteur: group: PPE name: PROUST Franck body: EP responsible: False committee: JURI date: 2013-02-20T00:00:00 committee_full: Legal Affairs rapporteur: group: EFD name: ZIOBRO Zbigniew body: EP responsible: False committee_full: Civil Liberties, Justice and Home Affairs committee: LIBE date: 2013-10-22T00:00:00
  • date: 2013-11-20T00:00:00 docs: url: http://www.europarl.europa.eu/oeil/popups/sda.do?id=23593&l=en type: Results of vote in Parliament title: Results of vote in Parliament url: http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P7-TA-2013-0479 type: Decision by Parliament, 1st reading/single reading title: T7-0479/2013 body: EP type: Results of vote in Parliament
  • date: 2014-02-17T00:00:00 body: CSL type: Council Meeting council: Agriculture and Fisheries meeting_id: 3293
  • date: 2014-02-17T00:00:00 body: EP type: End of procedure in Parliament
  • date: 2014-02-17T00:00:00 body: EP/CSL type: Act adopted by Council after consultation of Parliament
  • date: 2014-06-04T00:00:00 type: Final act published in Official Journal docs: url: http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32014D0318 title: Decision 2014/318 url: http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2014:165:TOC title: OJ L 165 04.06.2014, p. 0006
commission
  • body: EC dg: Taxation and Customs Union commissioner: ŠEMETA Algirdas
committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
International Trade
committee
INTA
date
2013-02-20T00:00:00
rapporteur
name: PROUST Franck group: European People's Party (Christian Democrats) abbr: PPE
shadows
name: KELLER Ska group: Greens/European Free Alliance abbr: Verts/ALE
committees/0
body
EP
responsible
False
committee_full
Environment, Public Health and Food Safety
committee
ENVI
committees/1
type
Committee Opinion
body
EP
associated
False
committee_full
Environment, Public Health and Food Safety
committee
ENVI
opinion
False
committees/1
body
EP
shadows
group: Verts/ALE name: KELLER Ska
responsible
True
committee
INTA
date
2013-02-20T00:00:00
committee_full
International Trade
rapporteur
group: PPE name: PROUST Franck
committees/2
type
Committee Opinion
body
EP
associated
False
committee_full
Legal Affairs
committee
JURI
date
2013-02-20T00:00:00
rapporteur
name: ZIOBRO Zbigniew group: Europe of Freedom and Democracy abbr: EFD
committees/2
body
EP
responsible
False
committee
JURI
date
2013-02-20T00:00:00
committee_full
Legal Affairs
rapporteur
group: EFD name: ZIOBRO Zbigniew
committees/3
type
Committee Opinion
body
EP
associated
False
committee_full
Civil Liberties, Justice and Home Affairs
committee
LIBE
opinion
False
committees/3
body
EP
responsible
False
committee_full
Civil Liberties, Justice and Home Affairs
committee
LIBE
council
  • body: CSL type: Council Meeting council: Agriculture and Fisheries meeting_id: 3293 url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=SMPL&ROWSPP=25&RESULTSET=1&NRROWS=500&DOC_LANCD=EN&ORDERBY=DOC_DATE+DESC&CONTENTS=3293*&MEET_DATE=17/02/2014 date: 2014-02-17T00:00:00
docs
  • date: 2013-04-23T00:00:00 docs: url: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:C:2014:032:TOC title: OJ C 032 04.02.2014, p. 0013 title: N7-0069/2014 summary: Opinion of the European Data Protection Supervisor on the proposal for a Council decision on the conclusion of the Agreement between the European Union and the Russian Federation on drug precursors . On 21 January 2013, the Commission adopted a proposal for a Council decision on the conclusion of the Agreement between the European Union and the Russian Federation on drug precursors. The proposal was sent to the EDPS for consultation on the same day. The EDPS had been previously consulted by the Commission. The present Opinion builds on the advice provided at that occasion and on the EDPS Opinion on the amendments to the Regulations on EU internal and external trade in drug precursors (the objective of which is to prevent the diversion from legitimate trade of the substances used to illicitly manufacture narcotic drugs and psychotropic substances). Data protection: the EDPS welcomes the provisions on the protection of personal data in the text of the agreement and the inclusion in the Annex of data protection principles to be respected by the Parties. The EDPS suggests including an explicit reference to the applicability of EU national laws implementing Directive 95/46/EC to the transfers of personal data by the EU to Russian authorities and to the processing of personal data by EU authorities. The EDPS also recommends specifying all the categories of personal data that might be exchanged. Furthermore, additional safeguards, such as shorter retention periods and stricter security measures should be included in the agreement or in Annex II for data relating to suspect transactions. Additional provisions: the EDPS also recommends the inclusion of the following provisions: · adding the provisions on ‘data security’ and the specific requirements for processing ‘sensitive data’; · specifying the procedures for making effective the principles of ‘transparency’ and ‘rights of access, rectification, erasure and blocking of data’ in the text of the agreement or in the Annex; · as regards ‘ onward transfers’ , it should be added that the competent authorities of the Parties should not transfer personal data to other national recipients unless the recipient provides adequate protection and for the purposes for which the data have been transmitted; · as regards the principle of ‘redress’, it should be specified that the term ‘competent authorities’, used in the rest of the agreement in a different context, refers here to authorities competent for the protection of personal data and the supervision of their processing; · the relevant authorities and the practical information on existing remedies should be mentioned in the agreement or at least in letters exchanged between the parties or in documents accompanying the agreement; · as regards the principle on ‘exceptions to the rights of transparency and direct access’: it should be specified that, in cases where the right of access cannot be granted to data subjects, indirect access through EU national data protection authorities should be provided. It should also be specified that the data protection supervisory authorities of the Parties should jointly review the implementation of the agreement, either in the framework of the joint follow-up expert group, or as a separate process. In addition, if the independence of the relevant Russian supervisory authority is not sufficiently established, it should be specified that EU national data protection authorities should be involved in the supervision of the implementation of the agreement by Russian authorities. The results of the review should be reported to the European Parliament and to the Council, where needed with full respect of confidentiality. The EDPS also recommends completing Article 12 of the agreement with a clause allowing any Party to suspend or terminate the agreement in the event of a breach of the other Party's obligations under the agreement, including as regards compliance with the data protection principles. type: Document attached to the procedure body: EDPS
  • date: 2013-04-30T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE508.205&secondRef=02 title: PE508.205 committee: JURI type: Committee opinion body: EP
  • date: 2013-05-27T00:00:00 docs: url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=8178%2F13&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC title: 08178/2013 type: Document attached to the procedure body: CSL
  • date: 2013-09-25T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE514.575 title: PE514.575 type: Committee draft report body: EP
  • date: 2013-05-28T00:00:00 docs: url: http://www.connefof.europarl.europa.eu/connefof/app/exp/COM(2013)0004 title: COM(2013)0004 type: Contribution body: PT_PARLIAMENT
events
  • date: 2013-01-21T00:00:00 type: Initial legislative proposal published body: EC docs: url: http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/com/2013/0004/COM_COM(2013)0004_EN.pdf title: COM(2013)0004 url: https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=COMfinal&an_doc=2013&nu_doc=4 title: EUR-Lex summary: PURPOSE: the conclusion of an agreement between the European Union and the Russian Federation on drug precursors. PROPOSED ACT: Council Decision. PARLIAMENT'S ROLE: Parliament's consent is required for the Council to conclude the agreement. BACKGROUND: on 23 March 2009, the Council authorised the Commission to open negotiations with the Russian Federation for an Agreement on drug precursors. Following the launch of negotiations in September 2009, four negotiating rounds took place. In September 2012, the text of the Agreement was finally agreed between the Parties. It is now appropriate to conclude this Agreement on behalf of the European Union. IMPACT ASSESSMENT: no impact assessment was undertaken. The Member States were, however, kept regularly informed on the negotiations at the most appropriate level of the Council on the Draft Agreement. LEGAL BASIS: Article 207 (4) first indent in conjunction with Article 218 (6) (a) of the Treaty on the Functioning of the European Union (TFEU). CONTENT: this Decision seeks to conclude an agreement between the European Union and Russia on drug precursors. Purpose of the Agreement: the Draft Agreement aims to strengthen the cooperation between the European Union and Russia to prevent diversion of drug precursors from the legal trade to counter illicit manufacture of narcotic drugs and psychotropic substances . Scope: from a technical point of view, it is stipulated that the Parties shall assist each other in the form and under the conditions provided for in the Agreement, in particular by: monitoring the trade between the Parties in the precursors with the aim of preventing their use for illicit purposes, providing mutual assistance for the purpose of prevention of diversion of such precursors. The measures shall apply to the precursors listed in Annex I of the Agreement (referred to as "scheduled precursors"). Exceptions to the obligation to provide mutual assistance: provisions are made in the Agreement for derogations from the principle of mutual assistance in cases where a Party is of the opinion that assistance under this Agreement would be likely to prejudice the sovereignty the security, the public policy or other essential interests. Exchange of personal data: as this Agreement may occasionally imply an exchange of personal data, it includes specific provisions on data protection in order to provide sufficient protection for citizens in the use of their data. An annex clarifies certain definitions or principles relating to data protection. Scientific and technical cooperation: Provisions are made to facilitate cooperation between the Parties with a view to the identification of new diversion methods, as well as appropriate counter-measures. Institutional framework: a Joint Follow-Up Expert Group is established which consists of the representatives of competent authorities of the Parties. It shall be responsible for the management of the Agreement and its proper implementation. It should be noted that unless otherwise provided by this Agreement, its provisions shall not affect the obligations of the Parties under any other international agreement. BUDGETARY IMPLICATION: the proposal has no budgetary implications for the Union budget. Nevertheless, it is stipulated in the Agreement that each Party shall shall bear the costs it incurs arising from the measures to implement the Agreement.
  • date: 2013-09-05T00:00:00 type: Legislative proposal published body: EC docs: url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=12221%2F13&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC title: 12221/2013 summary: PURPOSE: the conclusion of an agreement between the European Union and Russia on drug precursors. PROPOSED ACT: Council Decision. PARLIAMENT’S ROLE: Parliament’s consent is required for the Council to conclude the agreement. BACKGROUND: the European Union and the Russian Federation should strengthen their cooperation to prevent diversion of drug precursors from the legal trade, in order to counter the illicit manufacture of narcotic drugs and psychotropic substances. In accordance with a Council Decision, the Agreement between the European Union and the Russian Federation on drug precursors was signed on 4 June 2013, subject to its conclusion at a later date. The Agreement should ensure full respect of fundamental rights, in particular a high level of protection for the processing and transfer of personal data between the Parties to the Agreement. It is now appropriate to conclude this Agreement on behalf of the European Union. IMPACT ASSESSMENT: no impact assessment was undertaken. The Member States were, however, kept regularly informed on the negotiations at the most appropriate level of the Council on the Draft Agreement. LEGAL BASIS: Article 207 (4) first indent in conjunction with Article 218 (6) (a) of the Treaty on the Functioning of the European Union (TFEU). CONTENT: by this proposal, the Council is invited to adopt a decision on the conclusion of an agreement between the European Union and Russia on drug precursors. The text of the Agreement is attached to the proposed Decision. Its main characteristics may be summarised as follows: Purpose of the Agreement: the draft Agreement aims to strengthen the cooperation between the European Union and Russia to prevent diversion of drug precursors from the legal trade to counter illicit manufacture of narcotic drugs and psychotropic substances . Scope: from a technical point of view, it is stipulated that the Parties shall assist each other in the form and under the conditions provided for in the Agreement, in particular by: monitoring the trade between the Parties in the precursors with the aim of preventing their use for illicit purposes, providing mutual assistance for the purpose of prevention of diversion of such precursors. The measures shall apply to the precursors listed in Annex I of the Agreement (referred to as "scheduled precursors"). Implementation measures: the Parties shall inform each other in writing about their respective competent authorities. These authorities shall communicate directly with one another for the purposes of this Agreement. The competent authorities of the Parties shall inform each other on their own initiative whenever they have reasonable grounds to believe that scheduled precursors in legitimate trade between the Parties may be diverted to the illicit manufacture of narcotic drugs or psychotropic substances. The Parties shall within the scope of this agreement provide each other mutual assistance through exchange of information referred to in the draft Agreement to prevent the diversion of scheduled precursors to the illicit manufacture of narcotic drugs or psychotropic substances. They shall, in accordance with the legislation of the Parties, take appropriate steps to prevent diversion . Exceptions to the obligation to provide mutual assistance: provisions are made in the Agreement for derogations from the principle of mutual assistance in cases where a Party is of the opinion that assistance under this Agreement would be likely to prejudice the sovereignty the security, the public policy or other essential interests. Exchange of personal data: as this Agreement may occasionally imply an exchange of personal data, it includes specific provisions on data protection in order to provide sufficient protection for citizens in the use of their data. An annex clarifies certain definitions or principles relating to data protection. Scientific and technical cooperation: p rovisions are made to facilitate cooperation between the Parties with a view to the identification of new diversion methods, as well as appropriate counter-measures. Institutional framework: a Joint Follow-Up Expert Group is established which consists of the representatives of competent authorities of the Parties. It shall be responsible for the management of the Agreement and its proper implementation. Duration of the Agreement: this Agreement shall be concluded for five years at the end of which it is automatically/tacitly renewed for further successive five year periods until one of the Parties notifies the other Party in writing of its intention to terminate this present agreement. BUDGETARY IMPLICATION: the proposal has no budgetary implications for the Union budget. Nevertheless, it is stipulated in the Agreement that each Party shall bear the costs it incurs arising from the measures to implement the Agreement.
  • date: 2013-10-08T00:00:00 type: Committee referral announced in Parliament, 1st reading/single reading body: EP
  • date: 2013-10-14T00:00:00 type: Vote in committee, 1st reading/single reading body: EP
  • date: 2013-10-22T00:00:00 type: Committee report tabled for plenary, 1st reading/single reading body: EP docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A7-2013-342&language=EN title: A7-0342/2013 summary: The Committee on International Trade adopted the report by Franck PROUST (EPP, FR) on the draft Council Decision on the conclusion, on behalf of the European Union, of the Agreement between the European Union and the Russian Federation on drug precursors. It recommended that the European Parliament give its consent to the conclusion. It also indicated that it would be necessary to monitor its implementation and that it hoped for the conclusion to be followed up by other similar agreements with other third countries in the years to come.
  • date: 2013-11-20T00:00:00 type: Results of vote in Parliament body: EP docs: url: https://oeil.secure.europarl.europa.eu/oeil/popups/sda.do?id=23593&l=en title: Results of vote in Parliament
  • date: 2013-11-20T00:00:00 type: Decision by Parliament, 1st reading/single reading body: EP docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P7-TA-2013-0479 title: T7-0479/2013 summary: The European Parliament adopted a legislative resolution on the on the draft Council Decision on the conclusion, on behalf of the European Union, of the Agreement between the European Union and the Russian Federation on drug precursors. Parliament gave its consent to the conclusion of the Agreement.
  • date: 2014-02-17T00:00:00 type: Act adopted by Council after consultation of Parliament body: EP/CSL
  • date: 2014-02-17T00:00:00 type: End of procedure in Parliament body: EP
  • date: 2014-06-04T00:00:00 type: Final act published in Official Journal summary: PURPOSE: the conclusion of an agreement between the European Union and the Russian Federation on drug precursors. NON-LEGISLATIVE ACT: Council Decision 2014/318/EU on the conclusion, on behalf of the European Union, of the Agreement between the European Union and the Russian Federation on drug precursors. BACKGROUND: the European Union and the Russian Federation should strengthen their cooperation to prevent diversion of drug precursors from the legal trade, in order to counter the illicit manufacture of narcotic drugs and psychotropic substances. In accordance with Council Decision 2013/263/EU, the Agreement between the European Union and the Russian Federation on drug precursors was signed on 4 June 2013, subject to its conclusion at a later date. The Agreement should ensure full respect of fundamental rights, in particular a high level of protection for the processing and transfer of personal data between the Parties to the Agreement. It is now appropriate to conclude this agreement on behalf of the European Union. CONTENT: by means of this decision, the Council approves on behalf of the European Union, with the consent of the European Parliament, an agreement between the European Union and the Russian Federation on drug precursors. Objective of the agreement: the agreement aims to strengthen the cooperation between the European Union and Russia to prevent diversion of drug precursors from the legal trade to counter illicit manufacture of narcotic drugs and psychotropic substances . Scope: from a technical point of view, it is stipulated that the Parties shall assist each other in the form and under the conditions provided for in the Agreement, in particular by: · monitoring the trade between the Parties in the precursors with the aim of preventing their use for illicit purposes, · providing mutual assistance for the purpose of prevention of diversion of such precursors. The measures shall apply to the precursors listed in Annex I of the Agreement (referred to as "scheduled precursors"). Implementing measures: it is envisaged that the Parties shall inform each other in writing about their respective competent authorities. These authorities shall communicate directly with one another for the purposes of this Agreement. The competent authorities of the Parties shall inform each other on their own initiative whenever they have reasonable grounds to believe that scheduled precursors in legitimate trade between the Parties may be diverted to the illicit manufacture of narcotic drugs or psychotropic substances. Exceptions to the obligation to provide mutual assistance: provisions are made in the Agreement for derogations from the principle of mutual assistance in cases where a Party is of the opinion that assistance under this Agreement would be likely to prejudice the sovereignty the security, the public policy or other essential interests. Exchange of personal data: as this Agreement may occasionally imply an exchange of personal data, it includes specific provisions on data protection in order to provide sufficient protection for citizens in the use of their data. An annex clarifies certain definitions or principles relating to data protection. Scientific and technical cooperation: provisions are made to facilitate cooperation between the Parties with a view to the identification of new diversion methods, as well as appropriate counter-measures. Institutional framework: a Joint Follow-Up Expert Group is established which consists of the representatives of competent authorities of the Parties. It shall be responsible for the management of the Agreement and its proper implementation. Duration of the agreement: the agreement is concluded for a period of 5 years at the end of which it will be automatically/tacitly renewed for successive new periods of 5 years, until one of the Parties notifies the other in writing of its intention to terminate the agreement. It may be amended by common agreement. ENTRY INTO FORCE: the decision enters into force on 17.02.2014. The agreement enters into force on 1 April 2014. docs: title: Decision 2014/318 url: https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32014D0318 title: OJ L 165 04.06.2014, p. 0006 url: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2014:165:TOC
other
  • body: EC dg: url: http://ec.europa.eu/taxation_customs/index_en.htm title: Taxation and Customs Union commissioner: ŠEMETA Algirdas
procedure/Modified legal basis
Old
Rules of Procedure of the European Parliament EP 150
New
Rules of Procedure EP 150
procedure/dossier_of_the_committee
Old
INTA/7/11716
New
  • INTA/7/11716
procedure/final/url
Old
http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32014D0318
New
https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32014D0318
procedure/subject
Old
  • 4.20.04 Pharmaceutical products and industry
  • 6.20.02 Export/import control, trade defence
  • 6.20.03 Bilateral economic and trade agreements and relations
  • 7.30.30.04 Action to combat drugs and drug-trafficking
New
4.20.04
Pharmaceutical products and industry
6.20.02
Export/import control, trade defence, trade barriers
6.20.03
Bilateral economic and trade agreements and relations
7.30.30.04
Action to combat drugs and drug-trafficking
activities/0/docs/0/celexid
CELEX:52013PC0004:EN
activities/0/docs/0/celexid
CELEX:52013PC0004:EN
links/European Commission/title
Old
PreLex
New
EUR-Lex
activities/2/committees/1/date
2013-02-20T00:00:00
activities/2/committees/1/rapporteur
  • group: PPE name: PROUST Franck
activities/2/committees/1/shadows
  • group: Verts/ALE name: KELLER Ska
activities/2/committees/2/date
2013-02-20T00:00:00
activities/2/committees/2/rapporteur
  • group: EFD name: ZIOBRO Zbigniew
activities/3/committees/1/date
2013-02-20T00:00:00
activities/3/committees/1/rapporteur
  • group: PPE name: PROUST Franck
activities/3/committees/1/shadows
  • group: Verts/ALE name: KELLER Ska
activities/3/committees/2/date
2013-02-20T00:00:00
activities/3/committees/2/rapporteur
  • group: EFD name: ZIOBRO Zbigniew
activities/4/committees/1/date
2013-02-20T00:00:00
activities/4/committees/1/rapporteur
  • group: PPE name: PROUST Franck
activities/4/committees/1/shadows
  • group: Verts/ALE name: KELLER Ska
activities/4/committees/2/date
2013-02-20T00:00:00
activities/4/committees/2/rapporteur
  • group: EFD name: ZIOBRO Zbigniew
activities/9/docs/1/url
Old
http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32014D0318&from=EN
New
http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2014:165:TOC
activities/9/text
  • PURPOSE: the conclusion of an agreement between the European Union and the Russian Federation on drug precursors.

    NON-LEGISLATIVE ACT: Council Decision 2014/318/EU on the conclusion, on behalf of the European Union, of the Agreement between the European Union and the Russian Federation on drug precursors.

    BACKGROUND: the European Union and the Russian Federation should strengthen their cooperation to prevent diversion of drug precursors from the legal trade, in order to counter the illicit manufacture of narcotic drugs and psychotropic substances.

    In accordance with Council Decision 2013/263/EU, the Agreement between the European Union and the Russian Federation on drug precursors was signed on 4 June 2013, subject to its conclusion at a later date.

    The Agreement should ensure full respect of fundamental rights, in particular a high level of protection for the processing and transfer of personal data between the Parties to the Agreement.

    It is now appropriate to conclude this agreement on behalf of the European Union.

    CONTENT: by means of this decision, the Council approves on behalf of the European Union, with the consent of the European Parliament, an agreement between the European Union and the Russian Federation on drug precursors.

    Objective of the agreement: the agreement aims to strengthen the cooperation between the European Union and Russia to prevent diversion of drug precursors from the legal trade to counter illicit manufacture of narcotic drugs and psychotropic substances.

    Scope: from a technical point of view, it is stipulated that the Parties shall assist each other in the form and under the conditions provided for in the Agreement, in particular by:

    ·         monitoring the trade between the Parties in the precursors with the aim of preventing their use for illicit purposes,

    ·         providing mutual assistance for the purpose of prevention of diversion of such precursors.

    The measures shall apply to the precursors listed in Annex I of the Agreement (referred to as "scheduled precursors").

    Implementing measures: it is envisaged that the Parties shall inform each other in writing about their respective competent authorities. These authorities shall communicate directly with one another for the purposes of this Agreement. The competent authorities of the Parties shall inform each other on their own initiative whenever they have reasonable grounds to believe that scheduled precursors in legitimate trade between the Parties may be diverted to the illicit manufacture of narcotic drugs or psychotropic substances.

    Exceptions to the obligation to provide mutual assistance: provisions are made in the Agreement for derogations from the principle of mutual assistance in cases where a Party is of the opinion that assistance under this Agreement would be likely to prejudice the sovereignty the security, the public policy or other essential interests.

    Exchange of personal data: as this Agreement may occasionally imply an exchange of personal data, it includes specific provisions on data protection in order to provide sufficient protection for citizens in the use of their data. An annex clarifies certain definitions or principles relating to data protection.

    Scientific and technical cooperation: provisions are made to facilitate cooperation between the Parties with a view to the identification of new diversion methods, as well as appropriate counter-measures.

    Institutional framework: a Joint Follow-Up Expert Group is established which consists of the representatives of competent authorities of the Parties. It shall be responsible for the management of the Agreement and its proper implementation.

    Duration of the agreement: the agreement is concluded for a period of 5 years at the end of which it will be automatically/tacitly renewed for successive new periods of 5 years, until one of the Parties notifies the other in writing of its intention to terminate the agreement. It may be amended by common agreement.

    ENTRY INTO FORCE: the decision enters into force on 17.02.2014. The agreement enters into force on 1 April 2014.

committees/1/date
2013-02-20T00:00:00
committees/1/rapporteur
  • group: PPE name: PROUST Franck
committees/1/shadows
  • group: Verts/ALE name: KELLER Ska
committees/2/date
2013-02-20T00:00:00
committees/2/rapporteur
  • group: EFD name: ZIOBRO Zbigniew
activities/2/committees/1/date
2013-02-20T00:00:00
activities/2/committees/1/rapporteur
  • group: EPP name: PROUST Franck
activities/2/committees/1/shadows
  • group: Verts/ALE name: KELLER Franziska
activities/2/committees/2/date
2013-02-20T00:00:00
activities/2/committees/2/rapporteur
  • group: EFD name: ZIOBRO Zbigniew
activities/3/committees/1/date
2013-02-20T00:00:00
activities/3/committees/1/rapporteur
  • group: EPP name: PROUST Franck
activities/3/committees/1/shadows
  • group: Verts/ALE name: KELLER Franziska
activities/3/committees/2/date
2013-02-20T00:00:00
activities/3/committees/2/rapporteur
  • group: EFD name: ZIOBRO Zbigniew
activities/4/committees/1/date
2013-02-20T00:00:00
activities/4/committees/1/rapporteur
  • group: EPP name: PROUST Franck
activities/4/committees/1/shadows
  • group: Verts/ALE name: KELLER Franziska
activities/4/committees/2/date
2013-02-20T00:00:00
activities/4/committees/2/rapporteur
  • group: EFD name: ZIOBRO Zbigniew
activities/9
date
2014-06-04T00:00:00
docs
type
Final act published in Official Journal
committees/1/date
2013-02-20T00:00:00
committees/1/rapporteur
  • group: EPP name: PROUST Franck
committees/1/shadows
  • group: Verts/ALE name: KELLER Franziska
committees/2/date
2013-02-20T00:00:00
committees/2/rapporteur
  • group: EFD name: ZIOBRO Zbigniew
procedure/Modified legal basis
Rules of Procedure of the European Parliament EP 150
procedure/final
url
http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32014D0318
title
Decision 2014/318
procedure/stage_reached
Old
Procedure completed, awaiting publication in Official Journal
New
Procedure completed
activities/1/docs/0/url
Old
http://register.consilium.europa.eu/content/out?lang=EN&typ=Advanced&cmsid=639&ff_COTE_DOCUMENT=12221%2F13&fc=REGAISEN&srm=25&md=100
New
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=12221%2F13&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
activities/1/docs/0/url
Old
http://register.consilium.europa.eu/servlet/driver?page=Result&lang=EN&typ=Advanced&cmsid=639&ff_COTE_DOCUMENT=12221%2F13&fc=REGAISEN&srm=25&md=100
New
http://register.consilium.europa.eu/content/out?lang=EN&typ=Advanced&cmsid=639&ff_COTE_DOCUMENT=12221%2F13&fc=REGAISEN&srm=25&md=100
activities/5/type
Old
Decision by Parliament, 1st reading/single reading
New
Results of vote in Parliament
activities/5/docs/1
url
http://www.europarl.europa.eu/oeil/popups/sda.do?id=23593&l=en
type
Results of vote in Parliament
title
Results of vote in Parliament
activities/6
date
2014-02-17T00:00:00
body
CSL
type
Council Meeting
council
Agriculture and Fisheries
meeting_id
3293
activities/7
date
2014-02-17T00:00:00
body
EP
type
End of procedure in Parliament
activities/8
date
2014-02-17T00:00:00
body
EP/CSL
type
Act adopted by Council after consultation of Parliament
procedure/stage_reached
Old
Awaiting final decision
New
Procedure completed, awaiting publication in Official Journal
procedure/Modified legal basis
Rules of Procedure of the European Parliament EP 138
activities/0
date
2013-01-21T00:00:00
docs
url: http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2013/0004/COM_COM(2013)0004_EN.pdf celexid: CELEX:52013PC0004:EN type: Initial legislative proposal published title: COM(2013)0004
body
EC
type
Initial legislative proposal
commission
DG: url: http://ec.europa.eu/taxation_customs/index_en.htm title: Taxation and Customs Union Commissioner: ŠEMETA Algirdas
activities/0/body
Old
EP
New
EC
activities/0/commission
  • DG: url: http://ec.europa.eu/taxation_customs/index_en.htm title: Taxation and Customs Union Commissioner: ŠEMETA Algirdas
activities/0/date
Old
2013-09-25T00:00:00
New
2013-01-21T00:00:00
activities/0/docs/0/celexid
CELEX:52013PC0004:EN
activities/0/docs/0/text
  • PURPOSE: the conclusion of an agreement between the European Union and the Russian Federation on drug precursors.

    PROPOSED ACT: Council Decision.

    PARLIAMENT'S ROLE: Parliament's consent is required for the Council to conclude the agreement.

    BACKGROUND: on 23 March 2009, the Council authorised the Commission to open negotiations with the Russian Federation for an Agreement on drug precursors. Following the launch of negotiations in September 2009, four negotiating rounds took place.

    In September 2012, the text of the Agreement was finally agreed between the Parties.

    It is now appropriate to conclude this Agreement on behalf of the European Union.

    IMPACT ASSESSMENT: no impact assessment was undertaken. The Member States were, however, kept regularly informed on the negotiations at the most appropriate level of the Council on the Draft Agreement.

    LEGAL BASIS: Article 207 (4) first indent in conjunction with Article 218 (6) (a) of the Treaty on the Functioning of the European Union (TFEU).

    CONTENT: this Decision seeks to conclude an agreement between the European Union and Russia on drug precursors.

    Purpose of the Agreement: the Draft Agreement aims to strengthen the cooperation between the European Union and Russia to prevent diversion of drug precursors from the legal trade to counter illicit manufacture of narcotic drugs and psychotropic substances.

    Scope: from a technical point of view, it is stipulated that the Parties shall assist each other in the form and under the conditions provided for in the Agreement, in particular by:

    • monitoring the trade between the Parties in the precursors with the aim of preventing their use for illicit purposes,
    • providing mutual assistance for the purpose of prevention of diversion of such precursors.

    The measures shall apply to the precursors listed in Annex I of the Agreement (referred to as "scheduled precursors").

    Exceptions to the obligation to provide mutual assistance: provisions are made in the Agreement for derogations from the principle of mutual assistance in cases where a Party is of the opinion that assistance under this Agreement would be likely to prejudice the sovereignty the security, the public policy or other essential interests.

    Exchange of personal data: as this Agreement may occasionally imply an exchange of personal data, it includes specific provisions on data protection in order to provide sufficient protection for citizens in the use of their data. An annex clarifies certain definitions or principles relating to data protection.

    Scientific and technical cooperation:

    Provisions are made to facilitate cooperation between the Parties with a view to the identification of new diversion methods, as well as appropriate counter-measures.

    Institutional framework: a Joint Follow-Up Expert Group is established which consists of the representatives of competent authorities of the Parties. It shall be responsible for the management of the Agreement and its proper implementation.

    It should be noted that unless otherwise provided by this Agreement, its provisions shall not affect the obligations of the Parties under any other international agreement.

    BUDGETARY IMPLICATION: the proposal has no budgetary implications for the Union budget. Nevertheless, it is stipulated in the Agreement that each Party shall shall bear the costs it incurs arising from the measures to implement the Agreement.

activities/0/docs/0/title
Old
PE514.575
New
COM(2013)0004
activities/0/docs/0/type
Old
Committee draft report
New
Initial legislative proposal published
activities/0/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE514.575
New
http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2013/0004/COM_COM(2013)0004_EN.pdf
activities/0/type
Old
Committee draft report
New
Initial legislative proposal published
activities/1
date
2013-05-27T00:00:00
docs
url: http://register.consilium.europa.eu/servlet/driver?page=Result&lang=EN&typ=Advanced&cmsid=639&ff_COTE_DOCUMENT=8178%2F13&fc=REGAISEN&srm=25&md=100 type: Document attached to the procedure title: 08178/2013
body
CSL
type
Document attached to the procedure
activities/2
date
2013-09-05T00:00:00
docs
url: http://register.consilium.europa.eu/servlet/driver?page=Result&lang=EN&typ=Advanced&cmsid=639&ff_COTE_DOCUMENT=12221%2F13&fc=REGAISEN&srm=25&md=100 type: Legislative proposal title: 12221/2013
body
CSL
type
Legislative proposal
activities/5/type
Old
Text adopted by Parliament, 1st reading/single reading
New
Decision by Parliament, 1st reading/single reading
activities/0/docs/0/celexid
CELEX:52013PC0004:EN
activities/0/docs/0/celexid
CELEX:52013PC0004:EN
activities/8/docs/0/url
http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P7-TA-2013-0479
activities/0/docs/0/celexid
CELEX:52013PC0004:EN
activities/0/docs/0/celexid
CELEX:52013PC0004:EN
activities/8/docs/0/text
  • The European Parliament adopted a legislative resolution on the on the draft Council Decision on the conclusion, on behalf of the European Union, of the Agreement between the European Union and the Russian Federation on drug precursors.

    Parliament gave its consent to the conclusion of the Agreement.

activities/8/docs
  • type: Decision by Parliament, 1st reading/single reading title: T7-0479/2013
activities/8/type
Old
Vote in plenary scheduled
New
Text adopted by Parliament, 1st reading/single reading
procedure/stage_reached
Old
Awaiting Parliament 1st reading / single reading / budget 1st stage
New
Awaiting final decision
procedure/Modified legal basis
Rules of Procedure of the European Parliament EP 138
procedure/legal_basis/0
Rules of Procedure of the European Parliament EP 138
activities/7/docs/0/text
  • The Committee on International Trade adopted the report by Franck PROUST (EPP, FR) on the draft Council Decision on the conclusion, on behalf of the European Union, of the Agreement between the European Union and the Russian Federation on drug precursors.

    It recommended that the European Parliament give its consent to the conclusion. It also indicated that it would be necessary to monitor its implementation and that it hoped for the conclusion to be followed up by other similar agreements with other third countries in the years to come.

activities/7/docs/0/url
http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A7-2013-342&language=EN
activities/1
date
2013-05-27T00:00:00
docs
url: http://register.consilium.europa.eu/servlet/driver?page=Result&lang=EN&typ=Advanced&cmsid=639&ff_COTE_DOCUMENT=8178%2F13&fc=REGAISEN&srm=25&md=100 type: Document attached to the procedure title: 08178/2013
body
CSL
type
Document attached to the procedure
activities/1/body
Old
EP
New
CSL
activities/1/date
Old
2013-09-25T00:00:00
New
2013-05-27T00:00:00
activities/1/docs/0/title
Old
PE514.575
New
08178/2013
activities/1/docs/0/type
Old
Committee draft report
New
Document attached to the procedure
activities/1/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE514.575
New
http://register.consilium.europa.eu/servlet/driver?page=Result&lang=EN&typ=Advanced&cmsid=639&ff_COTE_DOCUMENT=8178%2F13&fc=REGAISEN&srm=25&md=100
activities/1/type
Old
Committee draft report
New
Document attached to the procedure
activities/4/date
Old
2013-11-18T00:00:00
New
2013-09-25T00:00:00
activities/4/docs
  • url: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE514.575 type: Committee draft report title: PE514.575
activities/4/type
Old
Indicative plenary sitting date, 1st reading/single reading
New
Committee draft report
activities/9
date
2013-11-20T00:00:00
body
EP
type
Vote in plenary scheduled
activities/7
date
2013-10-22T00:00:00
docs
type: Committee report tabled for plenary, 1st reading/single reading title: A7-0342/2013
body
EP
committees
type
Committee report tabled for plenary, 1st reading/single reading
procedure/stage_reached
Old
Awaiting committee decision
New
Awaiting Parliament 1st reading / single reading / budget 1st stage
activities/2/docs/0/text
  • PURPOSE: the conclusion of an agreement between the European Union and Russia on drug precursors.

    PROPOSED ACT: Council Decision.

    PARLIAMENT’S ROLE: Parliament’s consent is required for the Council to conclude the agreement.

    BACKGROUND: the European Union and the Russian Federation should strengthen their cooperation to prevent diversion of drug precursors from the legal trade, in order to counter the illicit manufacture of narcotic drugs and psychotropic substances.

    In accordance with a Council Decision, the Agreement between the European Union and the Russian Federation on drug precursors was signed on 4 June 2013, subject to its conclusion at a later date.

    The Agreement should ensure full respect of fundamental rights, in particular a high level of protection for the processing and transfer of personal data between the Parties to the Agreement.

    It is now appropriate to conclude this Agreement on behalf of the European Union.

    IMPACT ASSESSMENT: no impact assessment was undertaken. The Member States were, however, kept regularly informed on the negotiations at the most appropriate level of the Council on the Draft Agreement.

    LEGAL BASIS: Article 207 (4) first indent in conjunction with Article 218 (6) (a) of the Treaty on the Functioning of the European Union (TFEU).

    CONTENT: by this proposal, the Council is invited to adopt a decision on the conclusion of an agreement between the European Union and Russia on drug precursors.

    The text of the Agreement is attached to the proposed Decision. Its main characteristics may be summarised as follows:

    Purpose of the Agreement: the draft Agreement aims to strengthen the cooperation between the European Union and Russia to prevent diversion of drug precursors from the legal trade to counter illicit manufacture of narcotic drugs and psychotropic substances.

    Scope: from a technical point of view, it is stipulated that the Parties shall assist each other in the form and under the conditions provided for in the Agreement, in particular by:

    • monitoring the trade between the Parties in the precursors with the aim of preventing their use for illicit purposes,
    • providing mutual assistance for the purpose of prevention of diversion of such precursors.

    The measures shall apply to the precursors listed in Annex I of the Agreement (referred to as "scheduled precursors").

    Implementation measures: the Parties shall inform each other in writing about their respective competent authorities. These authorities shall communicate directly with one another for the purposes of this Agreement. The competent authorities of the Parties shall inform each other on their own initiative whenever they have reasonable grounds to believe that scheduled precursors in legitimate trade between the Parties may be diverted to the illicit manufacture of narcotic drugs or psychotropic substances.

    The Parties shall within the scope of this agreement provide each other mutual assistance through exchange of information referred to in the draft Agreement to prevent the diversion of scheduled precursors to the illicit manufacture of narcotic drugs or psychotropic substances. They shall, in accordance with the legislation of the Parties, take appropriate steps to prevent diversion.

    Exceptions to the obligation to provide mutual assistance: provisions are made in the Agreement for derogations from the principle of mutual assistance in cases where a Party is of the opinion that assistance under this Agreement would be likely to prejudice the sovereignty the security, the public policy or other essential interests.

    Exchange of personal data: as this Agreement may occasionally imply an exchange of personal data, it includes specific provisions on data protection in order to provide sufficient protection for citizens in the use of their data. An annex clarifies certain definitions or principles relating to data protection.

    Scientific and technical cooperation: provisions are made to facilitate cooperation between the Parties with a view to the identification of new diversion methods, as well as appropriate counter-measures.

    Institutional framework: a Joint Follow-Up Expert Group is established which consists of the representatives of competent authorities of the Parties. It shall be responsible for the management of the Agreement and its proper implementation.

    Duration of the Agreement: this Agreement shall be concluded for five years at the end of which it is automatically/tacitly renewed for further successive five year periods until one of the Parties notifies the other Party in writing of its intention to terminate this present agreement.

    BUDGETARY IMPLICATION: the proposal has no budgetary implications for the Union budget. Nevertheless, it is stipulated in the Agreement that each Party shall bear the costs it incurs arising from the measures to implement the Agreement.

activities/3/docs/0/text
  • PURPOSE: the conclusion of an agreement between the European Union and Russia on drug precursors.

    PROPOSED ACT: Council Decision.

    PARLIAMENT’S ROLE: Parliament’s consent is required for the Council to conclude the agreement.

    BACKGROUND: the European Union and the Russian Federation should strengthen their cooperation to prevent diversion of drug precursors from the legal trade, in order to counter the illicit manufacture of narcotic drugs and psychotropic substances.

    In accordance with a Council Decision, the Agreement between the European Union and the Russian Federation on drug precursors was signed on 4 June 2013, subject to its conclusion at a later date.

    The Agreement should ensure full respect of fundamental rights, in particular a high level of protection for the processing and transfer of personal data between the Parties to the Agreement.

    It is now appropriate to conclude this Agreement on behalf of the European Union.

    IMPACT ASSESSMENT: no impact assessment was undertaken. The Member States were, however, kept regularly informed on the negotiations at the most appropriate level of the Council on the Draft Agreement.

    LEGAL BASIS: Article 207 (4) first indent in conjunction with Article 218 (6) (a) of the Treaty on the Functioning of the European Union (TFEU).

    CONTENT: by this proposal, the Council is invited to adopt a decision on the conclusion of an agreement between the European Union and Russia on drug precursors.

    The text of the Agreement is attached to the proposed Decision. Its main characteristics may be summarised as follows:

    Purpose of the Agreement: the draft Agreement aims to strengthen the cooperation between the European Union and Russia to prevent diversion of drug precursors from the legal trade to counter illicit manufacture of narcotic drugs and psychotropic substances.

    Scope: from a technical point of view, it is stipulated that the Parties shall assist each other in the form and under the conditions provided for in the Agreement, in particular by:

    • monitoring the trade between the Parties in the precursors with the aim of preventing their use for illicit purposes,
    • providing mutual assistance for the purpose of prevention of diversion of such precursors.

    The measures shall apply to the precursors listed in Annex I of the Agreement (referred to as "scheduled precursors").

    Implementation measures: the Parties shall inform each other in writing about their respective competent authorities. These authorities shall communicate directly with one another for the purposes of this Agreement. The competent authorities of the Parties shall inform each other on their own initiative whenever they have reasonable grounds to believe that scheduled precursors in legitimate trade between the Parties may be diverted to the illicit manufacture of narcotic drugs or psychotropic substances.

    The Parties shall within the scope of this agreement provide each other mutual assistance through exchange of information referred to in the draft Agreement to prevent the diversion of scheduled precursors to the illicit manufacture of narcotic drugs or psychotropic substances. They shall, in accordance with the legislation of the Parties, take appropriate steps to prevent diversion.

    Exceptions to the obligation to provide mutual assistance: provisions are made in the Agreement for derogations from the principle of mutual assistance in cases where a Party is of the opinion that assistance under this Agreement would be likely to prejudice the sovereignty the security, the public policy or other essential interests.

    Exchange of personal data: as this Agreement may occasionally imply an exchange of personal data, it includes specific provisions on data protection in order to provide sufficient protection for citizens in the use of their data. An annex clarifies certain definitions or principles relating to data protection.

    Scientific and technical cooperation: provisions are made to facilitate cooperation between the Parties with a view to the identification of new diversion methods, as well as appropriate counter-measures.

    Institutional framework: a Joint Follow-Up Expert Group is established which consists of the representatives of competent authorities of the Parties. It shall be responsible for the management of the Agreement and its proper implementation.

    Duration of the Agreement: this Agreement shall be concluded for five years at the end of which it is automatically/tacitly renewed for further successive five year periods until one of the Parties notifies the other Party in writing of its intention to terminate this present agreement.

    BUDGETARY IMPLICATION: the proposal has no budgetary implications for the Union budget. Nevertheless, it is stipulated in the Agreement that each Party shall bear the costs it incurs arising from the measures to implement the Agreement.

procedure/Modified legal basis
Rules of Procedure of the European Parliament EP 138
procedure/legal_basis/0
Rules of Procedure of the European Parliament EP 138
activities/5/committees/1/shadows
  • group: Verts/ALE name: KELLER Franziska
activities/6
date
2013-10-14T00:00:00
body
EP
type
Vote in committee, 1st reading/single reading
committees
committees/1/shadows
  • group: Verts/ALE name: KELLER Franziska
procedure/Modified legal basis
Rules of Procedure of the European Parliament EP 138
activities/0/docs/0/text
  • PURPOSE: the conclusion of an agreement between the European Union and the Russian Federation on drug precursors.

    PROPOSED ACT: Council Decision.

    PARLIAMENT'S ROLE: Parliament's consent is required for the Council to conclude the agreement.

    BACKGROUND: on 23 March 2009, the Council authorised the Commission to open negotiations with the Russian Federation for an Agreement on drug precursors. Following the launch of negotiations in September 2009, four negotiating rounds took place.

    In September 2012, the text of the Agreement was finally agreed between the Parties.

    It is now appropriate to conclude this Agreement on behalf of the European Union.

    IMPACT ASSESSMENT: no impact assessment was undertaken. The Member States were, however, kept regularly informed on the negotiations at the most appropriate level of the Council on the Draft Agreement.

    LEGAL BASIS: Article 207 (4) first indent in conjunction with Article 218 (6) (a) of the Treaty on the Functioning of the European Union (TFEU).

    CONTENT: this Decision seeks to conclude an agreement between the European Union and Russia on drug precursors.

    Purpose of the Agreement: the Draft Agreement aims to strengthen the cooperation between the European Union and Russia to prevent diversion of drug precursors from the legal trade to counter illicit manufacture of narcotic drugs and psychotropic substances.

    Scope: from a technical point of view, it is stipulated that the Parties shall assist each other in the form and under the conditions provided for in the Agreement, in particular by:

    • monitoring the trade between the Parties in the precursors with the aim of preventing their use for illicit purposes,
    • providing mutual assistance for the purpose of prevention of diversion of such precursors.

    The measures shall apply to the precursors listed in Annex I of the Agreement (referred to as "scheduled precursors").

    Exceptions to the obligation to provide mutual assistance: provisions are made in the Agreement for derogations from the principle of mutual assistance in cases where a Party is of the opinion that assistance under this Agreement would be likely to prejudice the sovereignty the security, the public policy or other essential interests.

    Exchange of personal data: as this Agreement may occasionally imply an exchange of personal data, it includes specific provisions on data protection in order to provide sufficient protection for citizens in the use of their data. An annex clarifies certain definitions or principles relating to data protection.

    Scientific and technical cooperation:

    Provisions are made to facilitate cooperation between the Parties with a view to the identification of new diversion methods, as well as appropriate counter-measures.

    Institutional framework: a Joint Follow-Up Expert Group is established which consists of the representatives of competent authorities of the Parties. It shall be responsible for the management of the Agreement and its proper implementation.

    It should be noted that unless otherwise provided by this Agreement, its provisions shall not affect the obligations of the Parties under any other international agreement.

    BUDGETARY IMPLICATION: the proposal has no budgetary implications for the Union budget. Nevertheless, it is stipulated in the Agreement that each Party shall shall bear the costs it incurs arising from the measures to implement the Agreement.

activities/5
date
2013-10-08T00:00:00
body
EP
type
Committee referral announced in Parliament, 1st reading/single reading
committees
procedure/dossier_of_the_committee
INTA/7/11716
procedure/stage_reached
Old
Preparatory phase in Parliament
New
Awaiting committee decision
activities/0/docs/0/text
  • PURPOSE: the conclusion of an agreement between the European Union and the Russian Federation on drug precursors.

    PROPOSED ACT: Council Decision.

    PARLIAMENT’S ROLE: Parliament’s consent is required for the Council to conclude the agreement.

    BACKGROUND: on 23 March 2009, the Council authorised the Commission to open negotiations with the Russian Federation for an Agreement on drug precursors. Following the launch of negotiations in September 2009, four negotiating rounds took place.

    In September 2012, the text of the Agreement was finally agreed between the Parties.

    It is now appropriate to conclude this Agreement on behalf of the European Union.

    IMPACT ASSESSMENT: no impact assessment was undertaken. The Member States were, however, kept regularly informed on the negotiations at the most appropriate level of the Council on the Draft Agreement.

    LEGAL BASIS: Article 207 (4) first indent in conjunction with Article 218 (6) (a) of the Treaty on the Functioning of the European Union (TFEU).

    CONTENT: this Decision seeks to conclude an agreement between the European Union and Russia on drug precursors.

    Purpose of the Agreement: the Draft Agreement aims to strengthen the cooperation between the European Union and Russia to prevent diversion of drug precursors from the legal trade to counter illicit manufacture of narcotic drugs and psychotropic substances.

    Scope: from a technical point of view, it is stipulated that the Parties shall assist each other in the form and under the conditions provided for in the Agreement, in particular by:

    • monitoring the trade between the Parties in the precursors with the aim of preventing their use for illicit purposes,
    • providing mutual assistance for the purpose of prevention of diversion of such precursors.

    The measures shall apply to the precursors listed in Annex I of the Agreement (referred to as "scheduled precursors").

    Exceptions to the obligation to provide mutual assistance: provisions are made in the Agreement for derogations from the principle of mutual assistance in cases where a Party is of the opinion that assistance under this Agreement would be likely to prejudice the sovereignty the security, the public policy or other essential interests.

    Exchange of personal data: as this Agreement may occasionally imply an exchange of personal data, it includes specific provisions on data protection in order to provide sufficient protection for citizens in the use of their data. An annex clarifies certain definitions or principles relating to data protection.

    Scientific and technical cooperation:

    Provisions are made to facilitate cooperation between the Parties with a view to the identification of new diversion methods, as well as appropriate counter-measures.

    Institutional framework: a Joint Follow-Up Expert Group is established which consists of the representatives of competent authorities of the Parties. It shall be responsible for the management of the Agreement and its proper implementation.

    It should be noted that unless otherwise provided by this Agreement, its provisions shall not affect the obligations of the Parties under any other international agreement.

    BUDGETARY IMPLICATION: the proposal has no budgetary implications for the Union budget. Nevertheless, it is stipulated in the Agreement that each Party shall shall bear the costs it incurs arising from the measures to implement the Agreement.

activities/0/docs/0/type
Old
Legislative proposal published
New
Initial legislative proposal published
activities/0/type
Old
Legislative proposal
New
Initial legislative proposal
activities/1
date
2013-05-27T00:00:00
docs
url: http://register.consilium.europa.eu/servlet/driver?page=Result&lang=EN&typ=Advanced&cmsid=639&ff_COTE_DOCUMENT=8178%2F13&fc=REGAISEN&srm=25&md=100 type: Document attached to the procedure title: 08178/2013
body
CSL
type
Document attached to the procedure
activities/2
date
2013-09-05T00:00:00
docs
url: http://register.consilium.europa.eu/servlet/driver?page=Result&lang=EN&typ=Advanced&cmsid=639&ff_COTE_DOCUMENT=12221%2F13&fc=REGAISEN&srm=25&md=100 type: Legislative proposal title: 12221/2013
body
CSL
type
Legislative proposal
activities/3
date
2013-09-05T00:00:00
docs
url: http://register.consilium.europa.eu/servlet/driver?page=Result&lang=EN&typ=Advanced&cmsid=639&ff_COTE_DOCUMENT=12221%2F13&fc=REGAISEN&srm=25&md=100 type: Legislative proposal published title: 12221/2013
type
Legislative proposal published
body
EC
commission
DG: url: http://ec.europa.eu/taxation_customs/index_en.htm title: Taxation and Customs Union Commissioner: ŠEMETA Algirdas
activities/1/date
Old
2013-06-21T00:00:00
New
2013-09-25T00:00:00
activities/2
date
2013-10-14T00:00:00
body
EP
type
Vote scheduled in committee, 1st reading/single reading
activities/2/date
Old
2013-09-05T00:00:00
New
2013-10-14T00:00:00
activities/3/date
Old
2013-10-21T00:00:00
New
2013-11-18T00:00:00
activities/1/docs/0/url
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE514.575
activities/1
date
2013-06-21T00:00:00
docs
type: Committee draft report title: PE514.575
body
EP
type
Committee draft report
activities/1
date
2013-09-05T00:00:00
body
EP
type
Vote scheduled in committee, 1st reading/single reading
activities/2
date
2013-10-21T00:00:00
body
EP
type
Indicative plenary sitting date, 1st reading/single reading
committees/1/date
2013-02-20T00:00:00
committees/1/rapporteur
  • group: EPP name: PROUST Franck
committees/2/date
2013-02-20T00:00:00
committees/2/rapporteur
  • group: EFD name: ZIOBRO Zbigniew
activities/0/docs/0/text
  • PURPOSE: the conclusion of an agreement between the European Union and the Russian Federation on drug precursors.

    PROPOSED ACT: Council Decision.

    PARLIAMENT’S ROLE: Parliament’s consent is required for the Council to conclude the agreement.

    BACKGROUND: on 23 March 2009, the Council authorised the Commission to open negotiations with the Russian Federation for an Agreement on drug precursors. Following the launch of negotiations in September 2009, four negotiating rounds took place.

    In September 2012, the text of the Agreement was finally agreed between the Parties.

    It is now appropriate to conclude this Agreement on behalf of the European Union.

    IMPACT ASSESSMENT: no impact assessment was undertaken. The Member States were, however, kept regularly informed on the negotiations at the most appropriate level of the Council on the Draft Agreement.

    LEGAL BASIS: Article 207 (4) first indent in conjunction with Article 218 (6) (a) of the Treaty on the Functioning of the European Union (TFEU).

    CONTENT: this Decision seeks to conclude an agreement between the European Union and Russia on drug precursors.

    Purpose of the Agreement: the Draft Agreement aims to strengthen the cooperation between the European Union and Russia to prevent diversion of drug precursors from the legal trade to counter illicit manufacture of narcotic drugs and psychotropic substances.

    Scope: from a technical point of view, it is stipulated that the Parties shall assist each other in the form and under the conditions provided for in the Agreement, in particular by:

    • monitoring the trade between the Parties in the precursors with the aim of preventing their use for illicit purposes,
    • providing mutual assistance for the purpose of prevention of diversion of such precursors.

    The measures shall apply to the precursors listed in Annex I of the Agreement (referred to as "scheduled precursors").

    Exceptions to the obligation to provide mutual assistance: provisions are made in the Agreement for derogations from the principle of mutual assistance in cases where a Party is of the opinion that assistance under this Agreement would be likely to prejudice the sovereignty the security, the public policy or other essential interests.

    Exchange of personal data: as this Agreement may occasionally imply an exchange of personal data, it includes specific provisions on data protection in order to provide sufficient protection for citizens in the use of their data. An annex clarifies certain definitions or principles relating to data protection.

    Scientific and technical cooperation:

    Provisions are made to facilitate cooperation between the Parties with a view to the identification of new diversion methods, as well as appropriate counter-measures.

    Institutional framework: a Joint Follow-Up Expert Group is established which consists of the representatives of competent authorities of the Parties. It shall be responsible for the management of the Agreement and its proper implementation.

    It should be noted that unless otherwise provided by this Agreement, its provisions shall not affect the obligations of the Parties under any other international agreement.

    BUDGETARY IMPLICATION: the proposal has no budgetary implications for the Union budget. Nevertheless, it is stipulated in the Agreement that each Party shall shall bear the costs it incurs arising from the measures to implement the Agreement.

activities
  • date: 2013-01-21T00:00:00 docs: url: http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2013/0004/COM_COM(2013)0004_EN.pdf celexid: CELEX:52013PC0004:EN type: Legislative proposal published title: COM(2013)0004 body: EC commission: DG: url: http://ec.europa.eu/taxation_customs/index_en.htm title: Taxation and Customs Union Commissioner: ŠEMETA Algirdas type: Legislative proposal
committees
  • body: EP responsible: False committee_full: Environment, Public Health and Food Safety committee: ENVI
  • body: EP responsible: True committee_full: International Trade committee: INTA
  • body: EP responsible: False committee_full: Legal Affairs committee: JURI
  • body: EP responsible: False committee_full: Civil Liberties, Justice and Home Affairs committee: LIBE
links
National parliaments
European Commission
other
  • body: EC dg: url: http://ec.europa.eu/taxation_customs/index_en.htm title: Taxation and Customs Union commissioner: ŠEMETA Algirdas
procedure
legal_basis
reference
2013/0005(NLE)
title
EU/Russia agreement: drug precursors
geographical_area
Russian Federation
stage_reached
Preparatory phase in Parliament
subtype
Consent by Parliament
type
NLE - Non-legislative enactments
subject